Invasive fungal infections in acute leukemia

Vijaya R. Bhatt, George M. Viola, Alessandra Ferrajoli

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Invasive fungal infection (IFI) is among the leading causes for morbidity, mortality, and economic burden for patients with acute leukemia. In the past few decades, the incidence of IFI has increased dramatically. The certainty of diagnosis of IFI is based on host factors, clinical evidence, and microbiological examination. Advancement in molecular diagnostic modalities (e.g. non-culture-based serum biomarkers such as β-glucan or galactomannan assays) and high-resolution radiological imaging has improved our diagnostic approach. The early use of these diagnostic tests assists in the early initiation of preemptive therapy. Nonetheless, the complexity of IFI in patients with leukemia and the limitations of these diagnostic tools still mandate astute clinical acumen. Its management has been further complicated by the increasing frequency of infection by non-Aspergillus molds (e.g. zygomycosis) and the emergence of drug-resistant fungal pathogens. In addition, even though the antifungal armamentarium has expanded rapidly in the past few decades, the associated mortality remains high. The decision to initiate antifungal treatment and the choice of antifungal therapy requires careful consideration of several factors (e.g. risk stratification, local fungal epidemiologic patterns, concomitant comorbidities, drug–drug interactions, prior history of antifungal use, overall cost, and the pharmacologic profile of the antifungal agents). In order to optimize our diagnostic and therapeutic management of IFI in patients with acute leukemia, further basic research and clinical trials are desperately needed.

Original languageEnglish (US)
Pages (from-to)231-247
Number of pages17
JournalTherapeutic Advances in Hematology
Volume2
Issue number4
DOIs
StatePublished - Aug 2011

Fingerprint

Leukemia
Zygomycosis
Glucans
Molecular Pathology
Mortality
Antifungal Agents
Therapeutics
Routine Diagnostic Tests
Comorbidity
Fungi
Biomarkers
Economics
Invasive Fungal Infections
Clinical Trials
Morbidity
Costs and Cost Analysis
Incidence
Infection
Serum
Research

Keywords

  • fungus
  • infection
  • leukemia
  • mold
  • yeast

ASJC Scopus subject areas

  • Hematology

Cite this

Invasive fungal infections in acute leukemia. / Bhatt, Vijaya R.; Viola, George M.; Ferrajoli, Alessandra.

In: Therapeutic Advances in Hematology, Vol. 2, No. 4, 08.2011, p. 231-247.

Research output: Contribution to journalReview article

Bhatt, Vijaya R. ; Viola, George M. ; Ferrajoli, Alessandra. / Invasive fungal infections in acute leukemia. In: Therapeutic Advances in Hematology. 2011 ; Vol. 2, No. 4. pp. 231-247.
@article{b403b9917bd944ad93f422a38e70a4b1,
title = "Invasive fungal infections in acute leukemia",
abstract = "Invasive fungal infection (IFI) is among the leading causes for morbidity, mortality, and economic burden for patients with acute leukemia. In the past few decades, the incidence of IFI has increased dramatically. The certainty of diagnosis of IFI is based on host factors, clinical evidence, and microbiological examination. Advancement in molecular diagnostic modalities (e.g. non-culture-based serum biomarkers such as β-glucan or galactomannan assays) and high-resolution radiological imaging has improved our diagnostic approach. The early use of these diagnostic tests assists in the early initiation of preemptive therapy. Nonetheless, the complexity of IFI in patients with leukemia and the limitations of these diagnostic tools still mandate astute clinical acumen. Its management has been further complicated by the increasing frequency of infection by non-Aspergillus molds (e.g. zygomycosis) and the emergence of drug-resistant fungal pathogens. In addition, even though the antifungal armamentarium has expanded rapidly in the past few decades, the associated mortality remains high. The decision to initiate antifungal treatment and the choice of antifungal therapy requires careful consideration of several factors (e.g. risk stratification, local fungal epidemiologic patterns, concomitant comorbidities, drug–drug interactions, prior history of antifungal use, overall cost, and the pharmacologic profile of the antifungal agents). In order to optimize our diagnostic and therapeutic management of IFI in patients with acute leukemia, further basic research and clinical trials are desperately needed.",
keywords = "fungus, infection, leukemia, mold, yeast",
author = "Bhatt, {Vijaya R.} and Viola, {George M.} and Alessandra Ferrajoli",
year = "2011",
month = "8",
doi = "10.1177/2040620711410098",
language = "English (US)",
volume = "2",
pages = "231--247",
journal = "Therapeutic Advances in Hematology",
issn = "2040-6207",
publisher = "Sage Publications",
number = "4",

}

TY - JOUR

T1 - Invasive fungal infections in acute leukemia

AU - Bhatt, Vijaya R.

AU - Viola, George M.

AU - Ferrajoli, Alessandra

PY - 2011/8

Y1 - 2011/8

N2 - Invasive fungal infection (IFI) is among the leading causes for morbidity, mortality, and economic burden for patients with acute leukemia. In the past few decades, the incidence of IFI has increased dramatically. The certainty of diagnosis of IFI is based on host factors, clinical evidence, and microbiological examination. Advancement in molecular diagnostic modalities (e.g. non-culture-based serum biomarkers such as β-glucan or galactomannan assays) and high-resolution radiological imaging has improved our diagnostic approach. The early use of these diagnostic tests assists in the early initiation of preemptive therapy. Nonetheless, the complexity of IFI in patients with leukemia and the limitations of these diagnostic tools still mandate astute clinical acumen. Its management has been further complicated by the increasing frequency of infection by non-Aspergillus molds (e.g. zygomycosis) and the emergence of drug-resistant fungal pathogens. In addition, even though the antifungal armamentarium has expanded rapidly in the past few decades, the associated mortality remains high. The decision to initiate antifungal treatment and the choice of antifungal therapy requires careful consideration of several factors (e.g. risk stratification, local fungal epidemiologic patterns, concomitant comorbidities, drug–drug interactions, prior history of antifungal use, overall cost, and the pharmacologic profile of the antifungal agents). In order to optimize our diagnostic and therapeutic management of IFI in patients with acute leukemia, further basic research and clinical trials are desperately needed.

AB - Invasive fungal infection (IFI) is among the leading causes for morbidity, mortality, and economic burden for patients with acute leukemia. In the past few decades, the incidence of IFI has increased dramatically. The certainty of diagnosis of IFI is based on host factors, clinical evidence, and microbiological examination. Advancement in molecular diagnostic modalities (e.g. non-culture-based serum biomarkers such as β-glucan or galactomannan assays) and high-resolution radiological imaging has improved our diagnostic approach. The early use of these diagnostic tests assists in the early initiation of preemptive therapy. Nonetheless, the complexity of IFI in patients with leukemia and the limitations of these diagnostic tools still mandate astute clinical acumen. Its management has been further complicated by the increasing frequency of infection by non-Aspergillus molds (e.g. zygomycosis) and the emergence of drug-resistant fungal pathogens. In addition, even though the antifungal armamentarium has expanded rapidly in the past few decades, the associated mortality remains high. The decision to initiate antifungal treatment and the choice of antifungal therapy requires careful consideration of several factors (e.g. risk stratification, local fungal epidemiologic patterns, concomitant comorbidities, drug–drug interactions, prior history of antifungal use, overall cost, and the pharmacologic profile of the antifungal agents). In order to optimize our diagnostic and therapeutic management of IFI in patients with acute leukemia, further basic research and clinical trials are desperately needed.

KW - fungus

KW - infection

KW - leukemia

KW - mold

KW - yeast

UR - http://www.scopus.com/inward/record.url?scp=84993804217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993804217&partnerID=8YFLogxK

U2 - 10.1177/2040620711410098

DO - 10.1177/2040620711410098

M3 - Review article

C2 - 23556092

AN - SCOPUS:84993804217

VL - 2

SP - 231

EP - 247

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

SN - 2040-6207

IS - 4

ER -